CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix Inc. is currently facing a challenging short-term outlook but is considered significantly undervalued for long-term investors. The stock is rated a 'Strong Buy' below $8.35, with a projected upside of approximately 114% to a fair value of $17.5. Future growth is anticipated to resume after a revenue trough in 2027, driven by product adoption and pipeline developments.
- ▪CorMedix is rated a 'Strong Buy' below $8.35.
- ▪The stock has an upside potential of approximately 114% to a fair value of $17.5.
- ▪The company is expected to experience a revenue trough in 2027 before growth resumes.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909296-cormedix-bleak-short-term-outlook-but-significantly-undervalued-for-the-long-run"},"author":{"@type":"Person","name":"Fundamental…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
